Top Hedge Fund News, Member Posts, Hedge Fund Daily Indices and more!

3yrs ago Hedge Fund hedgenordic Views: 631

Stockholm (HedgeNordic) – In September of 2018, biotech start-up ATAI Life Sciences completed a Series A financing round in the amount of $24.4 million to make psychedelic drugs to treat mental health disorders. Long/short equity fund Coeli Absolute European Equity, founded and managed by Mikael Petersson (pictured) out of Malmö, invested close to $1 million in the Series A round alongside a select group of investors that also featured well-known entrepreneur and venture capitalist Peter Thiel.

“Our fund was one of only circa ten institutions globally who participated in the first round two years ago,” Petersson tells HedgeNordic. “It’s only two years ago since we had the privilege, as one of only ca 10 institutional investors, to participate in ATAI’s first funding,” Petersson writes in a LinkedIn post. “Since then so much progress has been made.”

“Our fund was one of only circa ten institutions globally who participated in the first round two years ago. Since then so much progress has been made.”

After completing its Series B financing round of $43 million in March of this year, ATAI Life Sciences announced earlier this week the successful closing of its $125 million Series C financing round, which included $32 million of convertible debt that converted in connection with the Series C. The round was co-led by the family office of ATAI’s founder Christian Angermayer, Peter Thiel, and Catalio Capital Management, as well as other existing and new investors.

The proceeds from the financing will be primarily used to fund pre-clinical and clinical development of ATAI’s existing mental health programs, as well as expand its drug candidate pipeline and further advance ATAI’s platform technologies. ATAI Life Sciences operates as a drug development platform, aiming to acquire, incubate and develop psychedelics and other drugs to treat depression, anxiety, addiction and other mental health conditions.

According to an industry source cited by CNBC, the plan is to take ATAI Life Sciences public next year at a valuation of between $1 and $2 billion. “I would say we have all avenues open right now and haven’t yet finally decided which one we will take,” Florian Brand, the CEO & Co-Founder of ATAI Life Sciences, told CNBC on the future of ATAI.

Coeli Absolute European Equity can allocate up to ten percent of its portfolio to unlisted equities. “We have a mandate to invest up to ten percent in unlisted equities, but in reality, we target an allocation of five percent to this space on average,” Petersson recently told HedgeNordic. “We have maintained an allocation to unlisted stocks between two to four percent since the fund’s inception in early 2018.”

“We at the Coeli Absolute European Equity Fund are obviously very proud and happy investors and we look forward to a new exciting year in 2021.”

Before the Series C financing round, Coeli Absolute European Equity’s investment in ATAI Life Sciences accounted for about two percent of the fund’s assets under management, which currently stand at €74.3 million. “We are very happy and proud of the development journey of the firm,” Petersson tells HedgeNordic. “We at the Coeli Absolute European Equity Fund are obviously very proud and happy investors and we look forward to a new exciting year in 2021,” he added. “We are looking forward to an anticipated IPO next year.”

 

Picture by Rickard Kilström

Investing Alongside Peter Thiel on HedgeNordic.


Today's Hedge Fund Headlines:

Log In for More
Access Over 250K+ Industry Headlines, Posts and Updates
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.